Curzerenone attenuates neuroinflammation and oxidative stress via MAPK signaling pathway modulation: Network pharmacology and in vivo insights in a scopolamine-induced model of Alzheimer's disease

Alzheimer's disease (AD) is a grave global health challenge characterized by progressive cognitive decline and neuronal degeneration. This study aims to evaluate the therapeutic potential of curzerenone, a sesquiterpene compound, against AD using integrated network pharmacology, molecular docking, and an in vivo pharmacological evaluation strategy. Network pharmacology analyzed key targets involved in neuroinflammation, neurotransmission, and amyloidogenesis, including SOD2, NOS2, PTGS2, NFKB1, BACE1, and MAPK signaling components (ERK, JNK, p38), predicting a multi-faceted therapeutic potential of curzerenone. Molecular docking, followed by protein deformability results, confirmed the binding with MAPK signaling targets. Curzerenone was extracted using standard chromatographic methods, and its integrity was confirmed using HPLC, 1 H NMR, and 13 C NMR analyses. In vivo , curzerenone (1, 5, 10 mg/kg, i.p.) markedly improved spatial memory in a scopolamine-induced amnesia model assessed by Y-maze and MWM behavioral tests. FTIR analysis detected decreased inflammatory markers, while ELISA confirmed reduced proinflammatory cytokines (TNF-α, IL-1β). AChE assay ascertained curzerenone's ability to suppress ACHE activity. Biochemical analysis confirmed decreased levels of Oxidative markers (NO, MDA) while significantly enhancing antioxidant levels (GSH, GST, CAT, SOD). Additionally, qRT-PCR confirmed the downregulation of gene expression of inflammatory proteins, including ERK, JNK, p38, iNOS, and AP-1. • Curzerenone improves memory in scopolamine-induced amnesic mice. • FTIR spectroscopy showed reduced inflammation markers in brain tissue. • Computational studies identified MAPK pathway targets modulated by Curzerenone. • Targets identified include ERK, JNK, p38 MAPK, and iNOS. • AChE and cytokine levels decreased significantly after treatment. • Biochemical and qPCR assays validated neuroprotective and anti-inflammatory effects.

Authors

Institutions

Publication Details

Journal
Results in Chemistry
Published
2025-12-04
DOI
https://doi.org/10.1016/j.rechem.2025.102948
Citations
1
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
1.16
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Curzerenone attenuates neuroinflammation and oxidative stress via MAPK signaling pathway modulation: Network pharmacology and in vivo insights in a scopolamine-induced model of Alzheimer's disease

Zahid Raza, Salman Khan, Eun Kyoung Seo, Muhammad Ibrar Khan et al.
1 citations
Results in Chemistry
Alzheimer's disease research and treatments
1.16
article

Curzerenone attenuates neuroinflammation and oxidative stress via MAPK signaling pathway modulation: Network pharmacology and in vivo insights in a scopolamine-induced model of Alzheimer's disease

Zahid Raza, Salman Khan, Eun Kyoung Seo, Muhammad Ibrar Khan, Sana Zafar, Kifayat Ullah Shah, Fakhar ud Din, Han Bok Kwak, A.F. Sani
article en
1 citations

Abstract

Alzheimer's disease (AD) is a grave global health challenge characterized by progressive cognitive decline and neuronal degeneration. This study aims to evaluate the therapeutic potential of curzerenone, a sesquiterpene compound, against AD using integrated network pharmacology, molecular docking, and an in vivo pharmacological evaluation strategy. Network pharmacology analyzed key targets involved in neuroinflammation, neurotransmission, and amyloidogenesis, including SOD2, NOS2, PTGS2, NFKB1, BACE1, and MAPK signaling components (ERK, JNK, p38), predicting a multi-faceted therapeutic potential of curzerenone. Molecular docking, followed by protein deformability results, confirmed the binding with MAPK signaling targets. Curzerenone was extracted using standard chromatographic methods, and its integrity was confirmed using HPLC, 1 H NMR, and 13 C NMR analyses. In vivo , curzerenone (1, 5, 10 mg/kg, i.p.) markedly improved spatial memory in a scopolamine-induced amnesia model assessed by Y-maze and MWM behavioral tests. FTIR analysis detected decreased inflammatory markers, while ELISA confirmed reduced proinflammatory cytokines (TNF-α, IL-1β). AChE assay ascertained curzerenone's ability to suppress ACHE activity. Biochemical analysis confirmed decreased levels of Oxidative markers (NO, MDA) while significantly enhancing antioxidant levels (GSH, GST, CAT, SOD). Additionally, qRT-PCR confirmed the downregulation of gene expression of inflammatory proteins, including ERK, JNK, p38, iNOS, and AP-1. • Curzerenone improves memory in scopolamine-induced amnesic mice. • FTIR spectroscopy showed reduced inflammation markers in brain tissue. • Computational studies identified MAPK pathway targets modulated by Curzerenone. • Targets identified include ERK, JNK, p38 MAPK, and iNOS. • AChE and cytokine levels decreased significantly after treatment. • Biochemical and qPCR assays validated neuroprotective and anti-inflammatory effects.

Results in ChemistryVol. 19
Quaid-i-Azam University (PK), Ewha Womans University (KR), Capital University of Science and Technology (PK)
Openalex Percentile: Top 16%
Alzheimer's disease research and treatments
1.16
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.